JW Shinyak Corp
KOSDAQ:067290
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JW Shinyak Corp
Income from Continuing Operations
JW Shinyak Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
JW Shinyak Corp
KOSDAQ:067290
|
Income from Continuing Operations
₩15.7B
|
CAGR 3-Years
125%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
53%
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩185.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
₩253.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩187.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
61%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩12B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Income from Continuing Operations
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
JW Shinyak Corp
Glance View
JW SHINYAK Corp. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2003-02-11. The Company’s main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.
See Also
What is JW Shinyak Corp's Income from Continuing Operations?
Income from Continuing Operations
15.7B
KRW
Based on the financial report for Dec 31, 2025, JW Shinyak Corp's Income from Continuing Operations amounts to 15.7B KRW.
What is JW Shinyak Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
53%
Over the last year, the Income from Continuing Operations growth was 208%. The average annual Income from Continuing Operations growth rates for JW Shinyak Corp have been 125% over the past three years , and 53% over the past ten years .
